Technical References
( MELANODERM )
720. SCREENING OF PLANT EXTRACTS FOR HUMAN TYROSINASE INHIBITING EFFECTS.
Kim1, M., Park1, J., Song1, K., Kim2, H.G., Koh2, J.-S. and Boo1, Y.C. 1Department of Molecular Medicine and Cell and Matrix Research Institute, BK21 Medical Education Program for Human Resources, Kyungpook National University School of Medicine, Daegu and 2Dermapro Skin Research Center, Dermapro Co. Ltd., Seoul, Korea. Inter. J. of Cosmetic Science, 34, 202–208 (2012).
717. FORMULATION OPTIMIZATION, SKIN IRRITATION, AND EFFICACY CHARACTERIZATION OF A NOVEL SKIN-LIGHTENING AGENT.
Jain1, P., Sonti2, S., Garruto2, J., Mehta2, R., & Banga1, A.K. 1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA, USA. 2SkinMedica Inc, Carlsbad, CA, USA. J. of Cosmetic Derm., 11, 101–110 (2012).
716. SIMULTANEOUS DETECTION AND SEMIQUANTIFICATION OF DNA DAMAGE IN NORMAL AND APOPTOTIC CELLS: TRIPLE-IMMUNOFLUORESCENT LABELING USING DAPI, ANTIBODIES, AND TUNEL.
Agrawal, A. and Godar, D.E. US Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, MD. Appl Immunohistochem Mol Morphol, 20, 4, (2012).
698. EBSELEN IS A NEW SKIN DEPIGMENTING AGENT THAT INHIBITS MELANIN BIOSYNTHESIS AND MELANOSOMAL TRANSFER.
Kasraee1, B., Nikolic1, D.S., Salomon1, D., Carraux1, P., Fontao1, L., Piguet1, V., Omrani2, G.R., Sorg1,3,O., and Saurat1,3, J-H. 1Department of Dermatology, Geneva University Hospital, Geneva, Switzerland; 2Endocrinology and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran; 3Swiss Centre for Applied Human Toxicology (SCAHT), Geneva, Switzerland. Experimental Derm., 21, 19-24, (2011).
695. HYPERPIGMENTATION IN HUMAN SOLAR LENTIGO IS PROMOTED BY HEPARANASE-INDUCED LOSS OF HEPARAN SULFATE CHAINS AT THE DERMAL–EPIDERMAL JUNCTION.
Iriyama, S., Ono, T., Aoki, H., Amano, S. Shiseido Research Center, 2-2-1 Hayabuchi, Tsuzuki-ku, Yokohama 224-8558, Japan Journal of Dermatological Science, 64, 223–228, (2011).
694. FGF2 REGULATES MELANOCYTES VIABILITY THROUGH THE STAT3-TRANSACTIVATED PAX3 TRANSCRIPTION.
Dong1,2,6, L., Li1,6, Y., Caol, J., Liu1, F. Pier1,7, E., Chen1, E., Xu3, Z., Chen4, C., Wang5, R-a., Cui1, R. 1Department of Dermatology, Boston University School of Medicine, 609 Albany Street, Boston, MA 02118, USA; 2Department of Respiratory, Qilu Hospital, Shangdong University School of Medicine, Jinan, Shandong, China; 3Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham School of Medicine, 17th Avenue South, Birmingham, Al 35233, USA; 4Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue Boston, MA 02215, USA and 5Department of Pathology, Fourth Military Medical University, Xian, Shanxi, China; 6These authors contributed equally to this work; 7Molecular Oncology Research Institute, Tufts Medical Center, 800 Washington Street, #5609, Boston, MA 02111, USA. Cell Death and Differentiation, 1-7, (2011).
668. RECONSTRUCTED HUMAN SKIN MODEL TO STUDY MELANOMA AT DIFFERENT STAGES OF PROGRESSION.
Kaluzhny, Y., Ayehunie, S., and Klausner, M. MatTek Corporation, Ashland, MA, USA. Presented at Soc. Invest. Derma., Meeting, May 2011. J. of Invest. Derma., (131, Suppl. 1, Abstract 771 (2011).
637. INSPECTION OF SKIN HEMODYNAMICS WITH HYPERSPECTRAL CAMERA.
Nagaoka1, T., Eikje2, N.S., Nakamura3, A., Aizawa3, K., Kiyohara4, Y., Ichikawa5, F., Yamazaki6, T., Doi, M., Nakamura6, K., Otsubo, S., Sota2, T. 1Shizuoka Cancer Research Institute, Japan; 2Dept. of Electrical Engineering and Bioscience, 3Advanced Research Institute for Science and Engineering, Waseda University, Shinjuku, Tokyo, Japan; 4Shizuoka Cancer Center Hospital, Shizuoka, Japan; 5JFE Techno-Research Corporation, Chiba, Japan; 6Mitaka Kohki Co., Ltd., Tokyo, Japan. 29th Annual International Conf. of IEEE EMBS, Lyon, France (2007).
620. THE FIBROBLAST-DERIVED PARACRINE FACTOR NEUREGULIN-1 HAS A NOVEL ROLE IN REGULATING THE CONSTITUTIVE COLOR AND MELANOCYTE FUNCTION IN HUMAN SKIN.
Choi1, W., Wolber2, R., Gerwat2, W., Mann2, T., Batzer2, J., Smuda2, C., Liu3, H., Kolbe2,L. and Hearing1, V.J. 1Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA 2R&D, Skin Research, Beiersdorf AG, Hamburg, 20245, Germany 3Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC 20007, USA. J. of Cell Science, 123, 3102-3111, 2010.
601. INHIBITORY EFFECTS OF Á-ARBUTIN ON MELANIN SYNTHESIS IN CULTURED HUMAN MELANOMA CELLS AND A THREE-DIMENSIONAL HUMAN SKIN MODEL.
Sugimoto1, K., Nishimura1, T., Nomura1,K., Sugimoto2, K., and Kurikia1, T. 1Biochemical Research Laboratory, Ezaki Glico Co., Ltd.; Osaka, Japan and 2Laboratory of Applied Molecular Biology, Division of Applied Biochemistry, Graduate School of Agriculture and Biological Sciences, Osaka Prefecture University, Osaka, Japan. Biol. Pharm. Bull., 27, 4, 510-514, 2004.
598. A ZN(LL)-GLYCINE COMPLEX SUPPRESSES UVB-INDUCED MELANIN PRODUCTION BY STIMULATING METALLOTHIONEIN EXPRESSION.
Ochiai1, Y., Kaburagi1, S., Okano1, Y., Masaki1, H., Ichihashi2, M., Funasaka3, Y. and Sakurai4, H. 1Cosmos Technical Center Co., Ltd, Tokyo, Japan. 2Sun Clinic, Sun Care Institute, Osaka, Japan. 3Division of Dermatology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. 4Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan. International J. of Cosmetic Science, 30, 105-112, 2008.
522. A LOTION CONTAINING UNDECYLENOYL PHENYLALANINE AND ERGOTHIONEINE REDUCES MELANIN LEVELS WITHOUT AFFECTING TISSUE VIABILITY IN ARTIFICIAL SKIN CONSTRUCTS.
Dong, K., Yarosh, D., Smiles, K., and Markova, N. AGI Dermatics, Freeport, NY, US. J Am Acad Dermatol, March 2009.
504. 1-(2,4-DIHYDROXYPHENYL)-3-(2,4-DIMETHOXY-3-METHYL-PHENYL)PROPANE, A NOVEL TYROSINASE INHIBITOR WITH STRONG DEPIGMENTING EFFECTS.
Nesterov1, A., Zhao1, J., Minter2, D., Hertel1, C., Ma1, W., Abeysinghe1, P., Hong1, M., and Jia1, Q. 1Unigen Pharmaceuticals, Inc.; 2660 Willamette Drive NE, Lacey, WA 98516, U.S.A.: and 2Chemistry Department, Texas Christian University; Fort Worth, TX 76129, USA. Chem. Pharm. Bull., 56(9) 1292-1296 (2008).
500. IDENTIFICATION OF QUINOLINES THAT INHIBIT MELANOGENESIS BY ALTERING TYROSINASE FAMILY TRAFFICKING.
Ni-Komatsu, L., Tong, C., Chen, G., Brindzei, N., and Orlow, S.J. The Ronald O. Perelman Department of Dermatology and the Department of Cell Biology, New York University School of Medicine, New York, New York (L.N.-K., C.X.T., N.B., S.J.O.); and PTC Therapeutics, South Plainfield, New Jersey (G.C.). Mol Pharmacol, 74, 1576-1586, (2008).
497. FORSKOLIN PROTECTS KERATINOCYTES FROM UVB-INDUCED APOPTOSIS AND INCREASES DNA REPAIR INDEPENDENT OF ITS EFFECTS ON MELANOGENESIS.
Passeron, T., Namiki, T., Passeron, H.J., Le Pape, E. and Hearing, V.J. Pigment Cell Biology Section, Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. J. of Invest. Dermatol., advance online publication, 26 June 2008.
490. QUERCETIN-INDUCED MELANOGENESIS IN A RECONSTITUTED THREE-DIMENSIONAL HUMAN EPIDERMAL MODEL.
Takeyama1, R., Takekoshi2, S., Nagata2, H., Osamura2, R.Y., & Kawana1, S. 1Department of Dermatology, Nippon Medical School, Sendagi 1-1-5, Bunkyou-ku Tokyo 113-8603, Japan. 2Department of Pathology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan. J. of Molecular Histology, 35, 157-165, 2004.
476. A COMPARISON OF TWO 4% HYDROQUINONE PRODUCTS ON MELANOCYTE MORPHOLOGY.
Dong, K.K., Canning, M.T., Smiles, K.A., and Yarosh, D.B. AGI Dermatics, Freeport, NY 11520. J. Am. Acad. Dermatol., P1022, February 2007.
474. INHIBITORY EFFECTS OF A NOVEL ASCORBIC DERIVATIVE, DISODIUM ISOSTEARYL 2-O-L-ASCORBYL PHOSPHATE ON MELANOGENESIS. Matsuda1, S., Shibayama1,2, H., Hisama1, M., Ohtsuki2, M., and Iwaki3, M.1Central Research Center, Toyo Beauty Co., Ltd.; 3-13-8 Higashinakamoto, Higashinari-ku, Osaka 537-0021, Japan: 2Department of Dermatorogy, Jichi Medical University; 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan: and 3Faculty of Pharmaceutical Sciences, Kinki University; 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, Japan.Chem. Pharm. Bull., 56(3) 292-297 (2008).
473. HUMAN SKIN RESPONSES TO UV RADIATION: PIGMENT IN THE UPPER EPIDERMIS PROTECTS AGAINST DNA DAMAGE IN THE LOWER EPIDERMIS AND FACILITATES APOPTOSIS.
Yamaguchi1, Y., Takahashi1, K., Zmudzka2, B.Z., Kornhauser3, A., Miller2, S.A., Tadokoro1, T., Berens1, W., Beer2, J.Z., and Hearing1, V.J. 1Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; 2Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland, USA; and 3Center for Food Safety and Applied Nutrition, U. S. Food and Drug Administration, College Park, Maryland, USA. FASEB J., 20,, E630-E639 (2006).
471. SOX9 IS A KEY PLAYER IN ULTRAVIOLET B-INDUCED MELANOCYTE DIFFERENTIATION AND PIGMENTATION.
Passeron1, T., Valencia1, J.C., Bertolotto2, C., Hoashi1, T., Le Pape1, E., Takahashi1, K., Ballotti2, R., and Hearing1, V.J. 1 1Pigment Cell Biology Section, Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814; and 2Unite 597, Institut National de la Sante et de la Recherche Medicale, Faculte de Medecine, Universite de Nice Sophia–Antipolis, 06103 Nice, France. PNAS, 104, 35, 13984-13989, (2007).
470. DICKKOPF 1 (DKK1) REGULATES SKIN PIGMENTATION AND THICKNESS BY AFFECTING WNT/â-CATENIN SIGNALING IN KERATINOCYTES.
Yamaguchi1,2,3, Y., Passeron1, T., Hoashi1, T., Watabe1, H., Rouzaud1, F., Yasumoto1, K., Hara1, T., Tohyama2, C., Katayama2, I., Miki1, T., and Hearing1, V.J. 1Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; 2Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan; and 3Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. FASEB J., 22, 000–000 (2008).
473. HUMAN SKIN RESPONSES TO UV RADIATION: PIGMENT IN THE UPPER EPIDERMIS PROTECTS AGAINST DNA DAMAGE IN THE LOWER EPIDERMIS AND FACILITATES APOPTOSIS.
Yamaguchi1, Y., Takahashi1, K., Zmudzka2, B.Z., Kornhauser3, A., Miller2, S.A., Tadokoro1, T., Berens1, W., Beer2, J.Z., and Hearing1, V.J. 1Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; 2Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland, USA; and 3Center for Food Safety and Applied Nutrition, U. S. Food and Drug Administration, College Park, Maryland, USA. FASEB J., 20,, E630-E639 (2006).
471. SOX9 IS A KEY PLAYER IN ULTRAVIOLET B-INDUCED MELANOCYTE DIFFERENTIATION AND PIGMENTATION.
Passeron1, T., Valencia1, J.C., Bertolotto2, C., Hoashi1, T., Le Pape1, E., Takahashi1, K., Ballotti2, R., and Hearing1, V.J. 1 1Pigment Cell Biology Section, Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814; and 2Unite 597, Institut National de la Sante et de la Recherche Medicale, Faculte de Medecine, Universite de Nice Sophia–Antipolis, 06103 Nice, France. PNAS, 104, 35, 13984-13989, (2007).
470. DICKKOPF 1 (DKK1) REGULATES SKIN PIGMENTATION AND THICKNESS BY AFFECTING WNT/â-CATENIN SIGNALING IN KERATINOCYTES.
Yamaguchi1,2,3, Y., Passeron1, T., Hoashi1, T., Watabe1, H., Rouzaud1, F., Yasumoto1, K., Hara1, T., Tohyama2, C., Katayama2, I., Miki1, T., and Hearing1, V.J. 1Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; 2Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan; and 3Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. FASEB J., 22, 000–000 (2008).
460. EVALUATION OF COSMETIC INGREDIENTS IN TISSUE ENGINEERED HUMAN SKIN IN VITRO.
Osborne, R., Mullins, L.A., Jarrold, B.B., McPhail, S., Robinson, L. The Procter & Gamble Company, Cincinnati, Ohio USA. Presented at American Association for Advancement of Science Annual Meeting (2007).
393. SUPPRESSED PERMEATION OF LINOLEIC ACID IN A LIPOSOMAL FORMULATION THROUGH RECONSTRUCTED SKIN TISSUE.
Shigeta1, Y., Imanaka2, H., Yonezawa3, S., Oku3, N., Baba1, N., Miakino2, T. 1Okayama University Graduate School of Natural Science and Technology, 3-1-1 Tsushimanaka, Okayama 700-8530, Japan. 2R&D, SUNSTAR INC, 3-1 Asahi-machi, Takatsuki 569-1195. 3Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Shizuoka 422-8526, Japan. Biol. Pharm. Bull., 27, 879-882, (2004).
387. PROTECTING THE SKIN AGAINST OZONE.
Gruber1, J.V., Tay1, A., Holtz2, R. 1Arch Personal Care Products, South Plainfield, NJ; 2BioInnovation Laboratories, Inc., McKinney, TX. Journal of Cosmetic Sciences, 56, (5), 348-349, (2005).
371. IN VITRO SKIN EQUIVALENT MODELS FOR TOXICITY TESTING.
Hayden, P.J., Ayehunie, S., Jackson, G.R., Kupfer-Lamore, S., Last, T.J., Klausner, M., Kubilus, J. MatTek Corporation, Ashland, MA, U.S.A. Published in Alternative Toxicological Methods. Editors H. Salem, S.A. Katz. CRC Press LLC, Boca Raton, FL, USA, 229-247 (2003).
329. A NATURAL NEW ACTIVE WHITENING MOLECULE.
Daffix1, C., Lemesle1, A, Robert1, C., Rabhi2, C.; Pouligon2, M., Jean2, D., Schwaab1, V. 1Department of Biology, LMD Pharmacognosie, Veyre-Monton, France. 2Department of Chemistry, LMD Pharmacognosie, Veyre-Monton, France. J. Invest. Dermatol., 122, (3), A157, Abstract #939, (2004).
326. HUMAN MELANOMA DEVELOPMENT IN RECONSTRUCTED SKIN MODELS.
Kubilus, J., Neal, P., Kaluzhny, Y., Sur, G., and Klausner, M. MatTek Corporation, Ashland, MA. J. Invest. Dermatol., 122, (3), A158, Abstract #945, (2004).
302. RECONSTITUTED 3-DIMENSIONAL HUMAN SKIN OF VARIOUS ETHNIC ORIGINS AS AN IN VITRO MODEL FOR STUDIES OF PIGMENTATION.
Yoon1,2, T.J., Lei2, T.C., Yamaguchi2, Y., Batzer3, J., Wolber3, R., Hearing2, V.J. 1Gyeongsang National University Hospital, Gyeongnam, South Korea, 2National Cancer Institute, Bethesda, MD, 3R&D Cosmed, Skin Research, Beiersdorf AG, Hamburg, Germany. Analytical Biochemistry, 318, (2), 260-269, (2003).
264. RESULTS USING MELANODERM™, AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES, DEMONSTRATE EFFICACY OF NOVEL SKIN LIGHTENING FORMULATIONS.
Klausner, M., Kubilus, J., Hayden, P.J., Last, T.J., DePaoliAmbrosi*, G. MatTek Corporation, Ashland, MA, *General Topics, s.r.l., San Felice del Benaco, Italy. Presented at Soc. Invest. Derm. Meeting, May (2002).
249. THE PROTEASE-ACTIVATED RECEPTOR 2 REGULATES PIGMENTATION VIA KERATINOCYTE-MELANOCYTE INTERACTIONS.
Seiberg, M., Paine, C., Sharlow, E., Andrade-Gordon, P., Costanzo, M., Eisinger, M., Shapiro, S.S. Skin Research Center, Johnson & Johnson CPWW, Skillman, New Jersey, 08558, USA. Exp. Cell Res., 254(1), 25-32, (2000).
227. IMPROVEMENTS TO MELANODERM™, AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES FOR SKIN LIGHTENING STUDIES.
Klausner, M., Neal, P., Breyfogle, B., Kubilus, J. MatTek Corp., Ashland, MA. J. Invest. Dermatol., 117, (2), 513, Abstract #740, (2001).
226. COMPARISON OF FUNCTIONAL PIGMENTATION ASSAYS.
Nip, J.S., Barratt, M.J. Skin Bioscience, Unilever Research US, Edgewater, NJ. Presented at the 10th annual meeting of the PanAmerican Society of Pigmented Cell Research, Minneapolis, June 14-17, (2001).
220. AN ALTERNATIVE APPROACH TO DEPIGMENTATION BY SOYBEAN EXTRACT VIA INHIBITION OF THE PAR-2 PATHWAY.
Paine, C., Sharlow, E., Liebel, F., Eisinger, M., Shapiro, S., Seiberg, M. Johnson and Johnson-Consumer Products Worldwide, Skin Research Center, Skillman, NJ. J. Invest. Dermatol., 116, (4) 587-595, (2000).
218. A CELL PIGMENTATION ASSAY SUITABLE FOR SCREENING OF COSMETIC RAW MATERIALS.
Costello, B. Collaborative Laboratories, Stonybrook, NY. Journal of Cosmetic Science, 51, (1) 71, (2000).
211. MELANODERM, AN EPIDERMAL TISSUE TO EVALUATE SKIN LIGHTENING AND DARKENING.
Klausner, M., Neal, P., Breyfogle, B., Kubilus, J. MatTek Corp., Ashland, MA. Presented at the 21st International Federation of Societies of Cosmetic Chemists Congress, Berlin, Germany, September 11 – 14, (2000).
206. USE OF MELANODERM™, AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES TO STUDY MODULATORS OF SKIN PIGMENTATION.
Klausner, M., Neal, P., Breyfogle, B., Kubilus, J. MatTek Corp., Ashland, MA. J. of Invest. Dermatol., 115, 553, Abstract #142, (2000).
200. INHIBITION OF MELANOSOME TRANSFER RESULTS IN SKIN LIGHTENING.
Seiberg, M., Paine, C., Sharlow, E., Andrade-Gordon, P., Costanzo*, M., Eisinger*, M., Shapiro, S.S. Skin Research Center, Johnson & Johnson CPWW, Skillman, New Jersey. U.S.A. *The R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, U.S.A. J. Invest. Dermatol., 115, 162-167, (2000).
196. USE OF MELANODERM™, AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES, FOR SKIN LIGHTENING STUDIES.
Klausner, M., Breyfogle, B., Neal, P., Kubilus, J. MatTek Corp., Ashland, Massachusetts J. of Invest. Dermatol., 114, 859, Abstract #661, (2000).
188. THE PROTEASE-ACTIVATED RECEPTOR 2 REGULATES PIGMENTATION VIA KERATINOCYTE-MELANOCYTE INTERACTIONS.
Seiberg, M., Paine, C., Sharlow, E., Andrade-Gordon, P., Costanzo, M., Eisinger, M., Shapiro, S.S. Skin Research Center, Johnson & Johnson CPWW, Skillman, NJ, 08558 USA. Exp. Cell Res., 254(1), 25-32, (2000).
177. MELANODERM™: AN EPIDERMAL TISSUE MODEL CONTAINING FUNCTIONAL MELANOCYTES.
Klausner, M., Neal, P., Breyfogle, B., Kubilus, J. MatTek Corp., Ashland, MA 01721, USA. Presented at the 17th International Pigment Cell Conference, Nagoya, Japan Oct 30-Nov 4, 1999. Also published in ATLA, 27, 299, (1999).
173. NEW RESULTS WITH MELANODERM™, AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES.
Klausner, M., Neal, P., Breyfogle, B., Kubilus, J.MatTek Corp., Ashland, MA.Presented at the 1999 Annual Meeting of the Society of Investigative Dermatology, Chicago, IL. Abstract published in J. Invest. Dermatol., 112, 629, Abstr. #639 (1999).
163. MELANODERM™, AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES.
Klausner, M., Neal, P., Breyfogle, B., Kubilus, J. MatTek Corp., Ashland, MA. Presented at IBC 3rd Annual Conference on "Cosmeceuticals", Short Hills, NJ, February 4-5, (1999).
160. AN IN VITRO METHOD FOR SCREENING SKIN-WHITENING PRODUCTS.
Majmudar, G., Jacob, G., Laboy, Y., Fisher, L. Mary Kay Holding Corp., Dallas, TX 75247. J. Cosmet. Sci., 361-367, (1998).
151. MATTEK'S TISSUE MODELS: NEW DEVELOPMENTS.
Klausner, M. MatTek Corp., Ashland, MA 01721. Presented at International Business Conference, "Latest In Vitro Testing Methods for Skin Care, Cosmetics, and Household Products," Washington, D.C., (1997).
122. INITIAL CHARACTERIZATION OF AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES.
Klausner, M., Kubilus, J., Neal, P.J. MatTek Corp., Ashland, MA. J. Invest. Dermatology, 104(4), 616, Abstr. # 370 (1995).
www.MatTek.co.kr
